Takeda UK

Takeda to bring UK salesforce in-house

pharmafile | January 15, 2016 | News story | Medical Communications, Sales and Marketing Takeda, field sales, marketing, sales, sales reps, salesforce 

Takeda UK is to bring all of its sales teams and support resources in-house and reintegrate its field salesforce into the company, effective 1st June 2016.

The field sales teams have been operated and managed by Ashfield Healthcare since 2004. The move will affect more than 70 members of staff in the company’s oncology key account manager (KAM) team, inflammatory bowel disease (IBD) team and the entire general medicine regional account director (RAD) and customer account specialist (CAS) teams, who will become Takeda employees.

This move will nearly double the number of Takeda employees in the UK, and the company says the decision “is part of an ambitious growth strategy to become an agile, specialty care provider focused on specific opportunities in oncology, IBD and diabetes.”

Adam Zaeske, managing director of Takeda UK and Ireland, says: “Takeda and Ashfield Healthcare were pioneers when the RAD/KAM model was conceived in 2004. The partnership has been a tremendous success and is still recognised with many major companies adopting a similar approach.”

“Today Takeda is at the cusp of a significant growth phase with specific opportunities in oncology, IBD and diabetes. We have made the strategic decision to integrate our sales teams as we recognise the critical role they play in growing our business and continuing to build a strong organisation.”

“This is an incredibly exciting time for Takeda as we transform our business as an agile, specialty care provider. This announcement is about forging one integrated team and is the latest step in that journey.”

Lilian Anekwe

Related Content

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …

Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan

ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company …

Takeda and HUTCHMED’s cancer drug shown to prolong overall survival

Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which …

Latest content